PMID- 14552902
OWN - NLM
STAT- MEDLINE
DCOM- 20031031
LR  - 20220310
IS  - 0014-4886 (Print)
IS  - 0014-4886 (Linking)
VI  - 183
IP  - 2
DP  - 2003 Oct
TI  - Glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor 
      sustain the axonal regeneration of chronically axotomized motoneurons in vivo.
PG  - 610-9
AB  - In contrast to injuries in the central nervous system, injured peripheral neurons 
      will regenerate their axons. However, axotomized motoneurons progressively lose 
      their ability to regenerate their axons, following peripheral nerve injury often 
      resulting in very poor recovery of motor function. A decline in neurotrophic 
      support may be partially responsible for this effect. The initial upregulation of 
      glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic 
      factor (BDNF) by Schwann cells of the distal nerve stump after nerve injury has 
      led to the speculation that they are important for motor axonal regeneration. 
      However, few experiments directly measure the effects of exogenous BDNF or GDNF 
      on motor axonal regeneration. This study provided the first direct and 
      quantitative evidence that long-term continuous treatment with exogenous GDNF 
      significantly increased the number of motoneurons which regenerate their axons, 
      completely reversing the negative effects of chronic axotomy. The beneficial 
      effect of GDNF was not dose-dependent. A combination of exogenous GDNF and BDNF 
      on motor axonal regeneration was significantly greater than either factor alone, 
      and this effect was most pronounced following long-term continuous treatment. The 
      ability of GDNF, either alone or in combination with BDNF, to increase the number 
      of motoneurons that regenerated their axons correlated well with an increase in 
      axon sprouting within the distal nerve stump. Thus long-term continuous treatment 
      with neurotrophic factors, such as GDNF and BDNF, can be used as a viable 
      treatment to sustain motor axon regeneration.
FAU - Boyd, J G
AU  - Boyd JG
AD  - Queen's University, Department of Anatomy and Cell Biology, ON, Kingston, Canada.
FAU - Gordon, T
AU  - Gordon T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Exp Neurol
JT  - Experimental neurology
JID - 0370712
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Gdnf protein, rat)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Nerve Growth Factors)
SB  - IM
MH  - Animals
MH  - Axons/*drug effects/physiology
MH  - Axotomy
MH  - Brain-Derived Neurotrophic Factor/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Female
MH  - Glial Cell Line-Derived Neurotrophic Factor
MH  - Infusion Pumps, Implantable
MH  - Motor Neurons/*drug effects/physiology
MH  - Nerve Growth Factors/administration & dosage/*pharmacology
MH  - Nerve Regeneration/*drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Treatment Outcome
EDAT- 2003/10/14 05:00
MHDA- 2003/11/01 05:00
CRDT- 2003/10/14 05:00
PHST- 2003/10/14 05:00 [pubmed]
PHST- 2003/11/01 05:00 [medline]
PHST- 2003/10/14 05:00 [entrez]
AID - S0014488603001833 [pii]
AID - 10.1016/s0014-4886(03)00183-3 [doi]
PST - ppublish
SO  - Exp Neurol. 2003 Oct;183(2):610-9. doi: 10.1016/s0014-4886(03)00183-3.